1. Apoptosis
  2. RIP kinase
  3. GSK963

GSK963 是一种手性的、强效的、选择性的受体相互作用蛋白 1 (RIP1) 酶的抑制剂,其 IC50 值为 29 nM。GSK963 对体外小鼠和人细胞的坏死具有强效和选择性的抑制作用。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

GSK963 Chemical Structure

GSK963 Chemical Structure

CAS No. : 2049868-46-2

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ¥990
In-stock
5 mg ¥900
In-stock
10 mg ¥1500
In-stock
25 mg ¥3000
In-stock
50 mg ¥4800
In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of GSK963:

MCE 顾客使用本产品发表的 1 篇科研文献

查看 RIP kinase 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC50 of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro[1].

IC50 & Target

IC50: 29 nM (RIP1 in FP binding assay)[1].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
L929 IC50
1 nM
Compound: GSK'963; 57
Anti-necroptic activity in mouse L929 cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptic activity in mouse L929 cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
[PMID: 36346971]
L929 IC50
3.1 nM
Compound: GSK963
Anti-necroptotic activity against TNFalph/Z-VAD-FMK-induced mouse L929 cells assessed as cell viability measured after 19 to 21 hrs by CellTiter-Glo luminescent cell viability assay
Anti-necroptotic activity against TNFalph/Z-VAD-FMK-induced mouse L929 cells assessed as cell viability measured after 19 to 21 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33964444]
Neutrophil IC50
0.9 nM
Compound: GSK'963; 57
Anti-necroptic activity in human neutrophil cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptic activity in human neutrophil cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
[PMID: 36346971]
U-937 IC50
4 nM
Compound: GSK963
Anti-necroptotic activity against TNFalph/Z-VAD-FMK-induced human U-937 cells assessed as cell viability measured after 19 to 21 hrs by CellTiter-Glo luminescent cell viability assay
Anti-necroptotic activity against TNFalph/Z-VAD-FMK-induced human U-937 cells assessed as cell viability measured after 19 to 21 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33964444]
U-937 IC50
4 nM
Compound: GSK'963; 57
Anti-necroptic activity in human U-937 cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
Anti-necroptic activity in human U-937 cells assessed as inhibition of TNF/zVAD induced necroptosis pretreated with compound for 30 mins followed by TNF/zVAD addition and measured after 19 to 21 hrs by celltiter-glo luminescent cell viability assay
[PMID: 36346971]
体外研究
(In Vitro)

GSK963 对 RIP1 的选择性超过 339 种其他激酶的 10,000 倍以上,对 IDO 缺乏可测量的活性,并且具有非活性对映体 GSK962,可用于确认靶向效应[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

GSK963 (2 mg/kg) 可完全恢复 TNF+zVAD 引起的温度损失。GSK963 (0.2 mg/kg) 也表现出显著的反应[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice[1].
Dosage: 0.2 mg/kg, 2 mg/kg, 10 mg/kg.
Administration: IP once.
Result: Protected mice from TNF+zVAD-induced hypothermia.
分子量

230.31

Formula

C14H18N2O

CAS 号
性状

固体

颜色

Light yellow to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 25 mg/mL (108.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.3420 mL 21.7099 mL 43.4197 mL
5 mM 0.8684 mL 4.3420 mL 8.6839 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (10.85 mM); 悬浊液; 超声助溶

    此方案可获得 2.5 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (10.85 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料
参考文献

GSK963 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.3420 mL 21.7099 mL 43.4197 mL 108.5493 mL
5 mM 0.8684 mL 4.3420 mL 8.6839 mL 21.7099 mL
10 mM 0.4342 mL 2.1710 mL 4.3420 mL 10.8549 mL
15 mM 0.2895 mL 1.4473 mL 2.8946 mL 7.2366 mL
20 mM 0.2171 mL 1.0855 mL 2.1710 mL 5.4275 mL
25 mM 0.1737 mL 0.8684 mL 1.7368 mL 4.3420 mL
30 mM 0.1447 mL 0.7237 mL 1.4473 mL 3.6183 mL
40 mM 0.1085 mL 0.5427 mL 1.0855 mL 2.7137 mL
50 mM 0.0868 mL 0.4342 mL 0.8684 mL 2.1710 mL
60 mM 0.0724 mL 0.3618 mL 0.7237 mL 1.8092 mL
80 mM 0.0543 mL 0.2714 mL 0.5427 mL 1.3569 mL
100 mM 0.0434 mL 0.2171 mL 0.4342 mL 1.0855 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
GSK963
目录号:
HY-103028A
需求量: